Philadelphia-based Berger Montague PC filed a securities fraud class action against ADMA Biologics, Inc. (NASDAQ: ADMA) on July 16, 2026. The suit covers investors who purchased or acquired ADMA common stock during a stated class period. Berger Montague, a national plaintiffs' firm, is soliciting inquiries from eligible shareholders.
Scope of the complaint
The complaint names ADMA Biologics as defendant. The covered investor class consists of those who purchased or acquired ADMA common stock during the specified window. Berger Montague's announcement did not detail the specific allegations, claimed damages, or the precise class period dates.
Next steps for shareholders
Berger Montague is inviting ADMA investors to contact the firm about participation. The July 16, 2026 notice directed affected shareholders to reach out to Berger Montague PC in Philadelphia.
Editor's note: The source announcement truncates before disclosing the class period dates and underlying allegations. This article reflects only the facts included in the published notice. Additional details are expected in subsequent filings.